August 1, 2023
Daiichi Sankyo said on July 31 that its first-quarter sales surged over 25%, driven by growth of key global products Enhertu (trastuzumab deruxtecan) and Lixiana (edoxaban) as well as a boon from the weaker yen. In the April-June period of...read more